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Over the past decade, researchers in the pharmaceutical industry and academia have made retrospective
analyses of successful drug campaigns in order to establish ‘‘rules’’ to guide the selection of new target
proteins. They have identified features that are considered undesirable and some that make targets ‘‘unli-
gandable.’’ This review focuses on the factors that make targets difficult: featureless binding sites, the
lack of hydrogen-bond donors and acceptors, the presence of metal ions, the need for adaptive changes
in conformation, and the lipophilicity of residues at the protein-ligand interface. Protein-protein interfaces
of multiprotein assemblies share many of these undesirable features, although those that involve concerted
binding and folding in their assembly have better defined pockets or grooves, and these can provide oppor-
tunities for identifying hits and for lead optimization. In some protein-protein interfaces conformational
changes—often involving rearrangement of large side chains such as those of tyrosine, tryptophan, or argi-
nine—are required to configure an appropriate binding site, and this may require tethering of the ligands until
higher affinity is achieved. In many enzymes, larger conformational rearrangements are required to form the
binding site, and these can make fragment-based approaches particularly difficult.What Makes a Difficult Target?
Two factors are usually considered to define a ‘‘druggable’’
protein target (Hopkins and Groom, 2002). The first is whether
its modulation has a therapeutic effect. This depends on the
analysis of the cellular pathways requiring a systems biological
approach and is outside the scope of this review. The second
concerns a more reductionist but equally important issue: the
ability of a protein target to bind a small drug-like molecule.
This is often known as ‘‘ligandability’’ (Edfeldt et al., 2011), it is
defined by the chemistry and structure of the target binding
site, and it is the focus of this review.
The ligandability of a protein is to some extent operationally
defined; it depends on the nature of the screening and design
approach. Conventional screening depends on a library of
drug-like compounds, usually selected to be consistent with
Lipinski’s ‘‘rule of 5’’ (Lipinski et al., 2001). In order to explore
chemical space efficiently the library must be chemically diverse
and large, usually comprising greater than 100,000 and often
more than one million compounds. Affinities of ‘‘hits’’ should
be micromolar or better, allowing roboticized bioassays of
receptor, enzyme, or whole-cell activity. An alternative is
structure-guided design of a ligand with appropriate drug-like
properties; this can exploit structures of the receptor protein or
ligand alone, or if available of the structure of a protein-ligand
complex. Such approaches include protein interaction mimetics
(Fletcher and Hamilton, 2005) and stapled helices (Stewart et al.,
2010). Increasingly frequently in recent years fragment-based
screening (Shuker et al., 1996; Blundell et al., 2002; Hajduk
and Greer, 2007; Murray and Blundell, 2010) is exploited with
small chemical libraries (Congreve et al., 2008; Hajduk and
Greer, 2007), perhaps with as few as 1000 compounds of
molecular weight less than 300 that are consistent with the
‘‘rule-of-three’’ (Congreve et al., 2003). Here, knowledge of the42 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rstructure of the protein target from X-ray or nuclear magnetic
resonance (NMR) methods is very important. This strategy
explores chemical space more efficiently, but because affinities
are often millimolar, it most often exploits biophysical assays as-
sessing binding to one partner of a functionally interacting pair,
for example, enzyme-substrate, receptor-ligand or protein-
protein, rather than disruption of an active protein complex
in vitro or in a cellular assay.
The optimization of candidate leads depends optimally on
binding sites that can match many pairs of atoms or groups in
stable interactions; this has generally been achieved in evolution
by creating concave grooves or pockets on the protein surface
that will accommodate small chemical entities. The interactions
need to compensate for loss of rotational and translational
entropy of the small chemical entity and for loss of conforma-
tional entropy in both partners, as the flexibility will be restrained.
However, water molecules are generally released and may
compensate though a positive entropic contribution. Isothermal
titration calorimetry can provide useful information on the nature
of these interactions and can provide insights into the major
determinants of the ligand-protein interactions. Fragments can
also induce conformational change but this is kinetically and/or
thermodynamically less likely than for drug-like molecules.
Nevertheless, ligand efficiency of fragments is often high as all
heavy atoms—C, N, O and S—can be more efficiently involved
in productive interactions. Hann’s complexity rule says that effi-
cient pairing of interacting atoms is less likely with larger drug-
like molecules (Hann et al., 2001).
This review focuses on difficult targets, where many of these
desirable features are absent and which would often be defined
as ‘‘unligandable.’’ We discuss the challenges of designing
ligands where binding sites are flat and featureless, and where
flexibility and chemistry of binding sites are not optimal.ights reserved
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Ligandability
Binding-site ligandability can be assessed either computation-
ally or experimentally. Currently available computational predic-
tors for classical receptor and enzyme targets are often based
upon the use of three-dimensional structural information of the
target proteins to define the concavity of putative binding sites.
These methods exploit geometrical scanning (PocketFinder,
which is based on Ligsite; Hendlich et al., 1997), PocketDepth
(Kalidas and Chandra, 2008), and Voronoi tessellation (Fpocket;
Le Guilloux et al., 2009). Many approaches identify favorable
interaction energies, often by using a van der Waals probe to
explore the protein-binding site as in Q-SiteFinder (Laurie and
Jackson, 2005) and i-SITE (Morita et al., 2008). Alternatively,
they use random forest classifiers and residue-based properties
(Site Predict; Bordner, 2009). A comparison of Finder, Fpocket,
PocketFinder, and SiteMap using structures of an impressively
large number (5,416) of protein-ligand complexes and the rele-
vant uncomplexed forms demonstrated that on the average
they identified 95% of the binding sites (Schmidtke et al.,
2010). Thornton, Laskowski, and colleagues have carried out
careful analyses of protein ligand-binding sites and combined
evolutionary-sequence conservation and three-dimensional
structure to predict protein-ligand-binding sites (Glaser et al.,
2006; Kahraman et al., 2007).
Some experimental approaches used to indicate ligandability
of a target measure hit rates, for example, in NMR-based or
X-ray-based fragment screens (Hajduk et al., 2005). Indeed in
an analysis of hit rates, best affinity and hit diversity, Edfeldt
et al. (2011) showed that fragment-screening-based ligandability
was an excellent predictor of success in high-throughput
screening and hit-to-lead project progression.
Selectivity
It is well known that drug-like synthetic molecules tend to have
fewer polar interactions and more lipophilic interactions with
their protein targets than those with other proteins, small
peptides and other natural molecules (Keseru¨ and Makara,
2009). However, they also have larger numbers of unmatched
nitrogen, oxygen, and sulfur atoms and show no correlation
between lipophilicity and the proportion of polar contacts
(Hann et al., 2001). These observations give some hope for opti-
mizing interactions, especially those with difficult targets
involving protein-protein interfaces of the kind discussed in the
next section. Recent reviews (Pe´rot et al., 2010) and an open
source repository for druggable and undruggable proteins
(Schmidtke and Barril, 2010) have assisted in updating analyses
of ‘‘druggability.’’ They show that that in addition to hydropho-
bicity, polar interactions play important roles.
A further and less discussed challenge in developing selective
inhibitors arises with metalloproteins, where the metal ion is
involved in catalytic mechanism and occurs in the binding site,
often as a central part of the ligand binding. From a drug design
perspective, the metal-binding site is the hot spot. Medicinal
chemists have traditionally focused their efforts on chemical
functions that directly interact with metals in the active site,
leading to competitive inhibition (Fisher and Mobashery, 2006),
sometimes giving specific inhibitors targeting Co (II) and Mn (II)
(Ye et al., 2004). However, such strategies have usually resulted
in broad-spectrum inhibitors as most of the metal-bindingChemistry & Biolgroups are highly polar groups like hydroxymates and carboxyl-
ates, which are bound rather unselectively (Yiotakis and Dive,
2002), and can hamper their bioavailability (Overall and Kleifeld,
2006).
Attempts to gain selectivity of metalloprotease inhibitors
have involved alternative hot spots and specific features of the
metalloproteins other than the metal ion (Devel et al., 2010).
HTS screens against matrix metalloproteinases have resulted
in nonchelating, and often noncompetitive class of inhibitors,
which offer better selectivity profiles (Chen et al., 2000; Johnson
et al., 2007; Pochetti et al., 2009; Engel et al., 2005). A hybrid
approach has been to attach a hydrophobic group specific for
a nonmetallic site through a linker to the metal-binding group
(Rouffet and Cohen, 2011). There remain major challenges in
discovering and developing selective metalloprotein inhibitors,
for example, in matrix metalloproteinases, where musculoskel-
etal toxicity thought to be arising from the target nondifferentia-
tion (Renkiewicz et al., 2003).
Targeting Protein-Protein Interfaces
Protein-Protein Interfaces
As we have seen most current prediction methods depend on
identification and scoring of pockets at the binding site for their
likelihood to accommodate a small molecule. Protein-protein
interfaces present special challenges in this respect as they
have fewer well-defined concave binding sites than classical
enzymes and receptors, and tend to be more lipophilic.
However, they comprise a diverse set of protein-binding inter-
faces and an increased effort has been made over the past
decade to predict druggable protein-protein interfaces (Wells
and McClendon, 2007).
The current interest in targeting the protein-protein interfaces
of multiprotein assemblies derives from their important and
extensive roles in the regulation of most biochemical pathways
involved in cell signaling, growth and survival (Venkatesan
et al., 2009). They are now recognized as therapeutic targets
that display greater structural and chemical diversity than protein
kinases and proteases that have comprised the classical targets
in these pathways. Although enzymes have led to the successful
development of many new drugs, most enzymes tend have
evolved as members of large superfamilies with common cata-
lytic residues, for example, the Asp-Thr/Ser-Gly motifs of as-
partic proteinases or common cofactor sites such as ATP sites
of protein kinases. Protein-protein interactions are also impor-
tant therapeutic targets in diseases where protein misfolding
and aggregation occurs, such as Huntington’s disease (Young,
2003) and Alzheimer’s disease (Bonda et al., 2010).
Structural Classification of Protein-Protein Interfaces
Multiprotein systems may be classified as obligate interactions,
where the subunits are not observed independently in vivo, or
nonobligate interactions where they are. As the latter class is
often dependent on location (Nooren and Thornton, 2003), it is
also useful to further classify complexes as transient and non-
transient, which define features of complexes once partners
are recognized. In the former case components and complexes
are in dynamic equilibrium, albeit with a range of binding affinities
and on- and off-rates (Nooren and Thornton, 2003).
Further important descriptors define whether an interaction
region comprises a discontinuous epitope, where strands ofogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 43
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a continuous epitope in which a continuous region of polypep-
tide, often comprising a single secondary structure element
(a helix or b strand), makes up the interaction interface.
Schwyzer suggested this distinction for polypeptide hormones
in the 1970s (Schwyzer et al., 1979). It was exemplified by
glucagon where biophysical and X-ray analyses (Sasaki et al.,
1975) together with NMR studies in a lipid-water interface (Braun
et al., 1983) suggested a disorder-to-order transition of the
polypeptide on receptor binding (Blundell, 1979; Blundell and
Wood, 1982). Such concerted binding-and-folding interactions
in proteins have been beautifully described by Wright and
coworkers, who have demonstrated their important roles in intra-
cellular pathways (Dyson and Wright, 2002). Transient protein-
protein interfaces potentially offer additional distinct sub-sites
for targeting using small molecule inhibitors (Blundell et al.,
2006) as described below for the RAD51-BRCA2 interaction
(Pellegrini et al., 2002).
Numerous computational resources describe protein-protein
interactions in terms of their three-dimensional protein structures
(Tuncbag et al., 2009). Useful databases include 3D Interaction
Domains (3DID; Stein et al., 2011), DAPID (Domain Annotated
Protein-protein Interaction Database; Chen et al., 2006), and
PICCOLO (Bickerton, 2009; Bickerton et al., 2011); http://www-
cryst.bioc.cam.ac.uk/piccolo). Such resources identify interfaces
clustered to reflect interface groups sharing equivalent residue
patches and relative geometries. Interactions are described at
the level of interacting pairs of atoms, residues, and polypeptide
chains. For example, PICCOLO includes 12 different interaction
types, which can be used to analyze residue propensity, hydrop-
athy, polarity, contact preference, and sequence entropy.
Hot Spots
In 1995 Clackson and Wells showed that a small subset of resi-
dues contributes most to the binding free energy at the protein-
protein interface on human growth hormone and its receptor
(Clackson and Wells, 1995) and further alanine-scanning
mutagenesis studies demonstrated that this was a general
phenomenon (Bogan and Thorn, 1998). Hot spots in protein-
protein interfaces can also be experimentally defined from frag-
ment screening, where binding sites for multiple small molecules
define the hot spot. Ciulli and co-workers have approached the
problem by examining the contributions to binding affinity of
the constituent fragments of a known ligand (Ciulli et al., 2006).
A very useful physical model (Robetta) has been described by
Kortemme and Baker (Kortemme and Baker, 2002), which
combines energetic, structural, and evolutionary information.
More recent predictions are based upon support vector machine
(SVM) methods (Lise et al., 2011) where the structure of
a complex is used to predict hot spot residues.
Bogan and Thorn (1998) found that hot spots in protein-protein
interfaces often include Tyr and Trp. These residues can con-
tribute aromatic pi-interactions with cations and CH-groups,
establish weak hydrogen bonds through aromatic hydrogens
with carbonyls and form hydrogen bonds through the indole
nitrogen of tryptophan and the phenolic hydroxyl of tyrosine
groups; they also have large hydrophobic surfaces that can
protect hydrogen bonds from water (Chakrabarti and Bhatta-
charyya, 2007). Arginine is also important, as it can form a range
of similar favorable interactions, in addition to ion pairs that force44 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rit to the periphery of an interacting interface. Aspartate and
asparagine with less side chain entropy are favored over gluta-
mate and glutamine. Bogan and Thorn have proposed an
O-ring theory where an energetically less important ring of resi-
dues surrounds the hot spots (Bogan and Thorn, 1998), and
this has been further developed by Nussinov and coworkers in
terms of ‘‘coupling’’ and ‘‘hot regions,’’ where highly packed
residues make it easier to remove water upon binding (Keskin
et al., 2005).
Targeting Protein-Protein Interactions
Many thoughtful approaches have been developed in response
to the need to target protein-protein interfaces in regulatory
multiprotein assemblies. These include proteomimetics that
use elegant chemistry to mimic protein surface structure
(Fletcher and Hamilton, 2005). For a-helical peptide molecular
recognition sites stapled peptides to crosslink adjacent residues
in the helix have proved resistant to proteolysis and useful for
several targets including BH3:Mcl-1 (Stewart et al., 2010),
p53:MDM2/X (Bernal et al., 2010), and MAML-1:Notch (Moeller-
ing et al., 2009). Further innovations include foldamers, which are
synthetic mimics of protein secondary structure elements (for
review, see Wilson, 2009), peptide aptamers (Buerger and
Groner, 2003), and antibody-like molecules (Traczewski and
Rudnicka, 2011).
Wells and co-workers describe interaction hot spots as ligand-
efficient ‘‘footholds,’’ with higher affinity achieved by through
‘‘cryptic’’ binding sites within the binding interface (Thanos
et al., 2006; Wells and McClendon, 2007). This is encouraging
for the use fragment-based drug discovery. However, although
fragments allow novel areas of chemical space to be explored
more efficiently, the initial hits have low affinity. Thus, in order
to disrupt protein-protein interfaces, they usually require teth-
ering (Erlanson et al., 2000) (see below), an approach that
has been pioneered byWells and co-workers, with some impres-
sive successes (Wells and McClendon, 2007). An alternative
fragment-based approach is to employ conventional fragment-
based screening (Shuker et al., 1996; Blundell et al., 2002;
Hajduk and Greer, 2007; Murray and Blundell, 2010). NMR,
X-ray crystallography, surface plasmon resonance, differential
scanning fluorimetry, or isothermal calorimetry (ITC) can then
be used to screen and validate fragment binding. However, for
protein-protein interfaces this depends onwhether the individual
subunits are globular and whether they can be stabilized as
monomers in solution. Fragment hits can subsequently be
evolved into larger lead-like and drug-like molecules with higher
affinity and potency.
There have been some useful efforts to classify small molecule
binding to protein-protein interfaces. TIMBAL, a database of
small molecules inhibiting multi-protein complexes (Higueruelo
et al., 2009) that allows comparisons of these small molecules
with drugs, chemical libraries and drug-like molecules in the
PDB. The inhibitors of protein-protein interfaces are on the
average bigger and more lipophilic and have fewer hydrogen
bonding features. 2P2IDB (http://2p2idb.cnrs-mrs.fr) is also
a hand-curated database of protein-protein complexes with
small molecules (Bourgeas et al., 2010), which confirms the
greater lipophilicity, and finds fewer charged residues and
a greater number of nonpolar atoms than at interfaces with no
known inhibitor. Interestingly the authors did not observe majorights reserved
Figure 1. Fragment Binding at a Protein-
Protein Interface of the Recombinase
RAD51 and BRCA2
Mode of interaction of fragments binding to the
phenylalanine-binding pocket of the RAD51 as
observed using X-ray crystallography in the
complex with the BRC4 peptide of BRCA2 (A) In-
dazole 5, (B) 4-methylester indole 4, (C) naph-
thalen-1-ol. (Figure by permission of D.S. Scott, M.
Marsh, A. Coyne, C. Abell, and M. Hyvonen.)
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to an inhibitor and the unliganded state.
We address the situation of conformational flexibility in
protein-protein interfaces below. Here, we describe one
example of the development of ligands to a protein-protein inter-
face that involves concerted folding and binding of a peptide to
a globular domain, very small pockets on a relatively featureless
binding interface and little conformational change on ligand
binding.
Targeting the Recombinase Rad51 Interface
with BRCA2
Knowledge of the structures of RAD51 (Pellegrini et al., 2002) and
its close orthologs in apo-form, in complexes of BRC repeats
and other short peptides and in oligomers have been central to
the development of fragment-based approaches targeting the
protein-protein interaction between the human recombinase
RAD51 and BRCA2. Fragment screening was initially carried
out using thermal shift with hits validated using both ligand-
observed NMR and X-ray crystallography (Figure 1). Different
humanized proteins that are soluble and monomeric have been
designed to be amenable to use with the different screening
methods, most importantly to engineer crystal forms with unob-
structed binding sites to be optimal for crystal soaking. ITC and
X-ray crystallography have been used to explore the thermody-
namics and structures of complexes with various peptides
designed around the BRC4 repeat. NMR and fluorescence
polarization detected competition assays have been exploited
to verify binding at the expected sites. Chimeras of peptides
and fragments with increased potency and molecules with high
nanomolar potency have been obtained and work is now under
way to target further local subsites to increase potency.
Targeting Transient and Flexible Binding Sites through
Conformational Change
Conformational Flexibility in Binding Sites
Many binding sites are induced by the ligand or alternatively one
conformer is stabilized from an ensemble on ligand recognition.
For enzymes, this may correspond to the stabilization of a loop,
which is brought transiently close to the ligand during catalysis,
or alternatively a hinge-bending movement of a domain that
naturally occurs on binding of cofactor or substrate. However,
in many proteins the induced binding site does not have an
obvious functional role in living organisms.
Exploiting conformational flexibility presents challenges for
most structure-based methods, but particularly for fragment-
based approaches where the binding energy of the first hit rarely
stabilizes the necessary conformation. Thus, tethered fragmentsChemistry & Biolare often exploited or the binding site stabilized in the absence of
the ligand, for example, in a crystal lattice (Wells andMcClendon,
2007). We now consider these challenging situations in turn.
Transient Active Sites
AroD is an essential enzyme from the shikimate pathway, which
is involved in aromatic amino acid synthesis in some microor-
ganisms. The absence of this pathway in humans makes the
enzymes attractive targets for discovering anti-infectives
(McConkey, 1999; Parish and Stoker, 2002). The active site of
AroD is located in a cleft (Harris et al., 1993), but the catalytically
important loop (Krell et al., 1995) is not seen in the electron
density of the apo-form of the protein (Gourley et al., 1999).
When the substrate is bound (Dias et al., 2011), the catalytic resi-
dues are brought into close proximity to the substrate. For this
target fragment binding has proved unsuccessful. A partially
formed AroD active site is required, which is induced only by
designing substrate analogs (Dias et al., 2011; Gonza´lez-Bello
and Castedo, 2007; Tizo´n et al., 2011). X-ray structures of
successful competitive inhibitors bound to the aroD show that
the residues from the loop region are ordered only in the case
of high affinity ligands (Figure 2).
The attempts to design inhibitors of shikimate kinase, a further
enzyme from the shikimate pathway, highlight the challenges
when a natural ligand or cofactor must bind in order to bring
about domain reorganization. Shikimate kinase belongs to the
nucleoside monophosphate kinase family, which catalyze the
phosphorylation of small molecules using ATP as a cofactor.
The several crystal structures of shikimate kinase (Dhaliwal
et al., 2004; Cheng et al., 2005; Dias et al., 2007) represent
various stages in the catalytic mechanism (Hartmann et al.,
2006) and define conformational changes that reposition the
ATP-binding domain, the shikimate-binding domain and the P
loop (Krell et al., 2001) upon binding ATP and shikimate. Figure 3
shows that, in unliganded structure of the Mycobacterium
tuberculosis shikimate kinase (PDB ID: 2IYT), the entire active
site is open. Movements of the two domains relative to each
other when the substrates bind create a more ligandable catalyt-
ically competent active site. Again, substrate analog or drug-like
screening approaches are likely to be more effective than frag-
ment-based approaches that have proved challenging in our
hands.
Induced Binding Sites
Some of the most successful attempts to bind molecules at
protein-protein interfaces have led to a reorganization of surface
residues and creation of a ligand-binding cavity (Wells and
McClendon, 2007). For fragment-based design these have often
entailed tethering the fragment. An example is the 60 nM smallogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 45
Figure 2. Conformational Flexibility in the Active
Site of the Enzyme aroD
(A) Structure of aroD in unliganded form (PDB ID: 2DHQ),
shown as the protein surface with secondary structure in
red color. In unliganded aroD the catalytically important
loop illustrated by dashed line, which forms the part of
the active site, is disordered and cannot be seen in the
electron density of the X-ray crystal structure, whereas the
partially formed site is highlighted by yellow circle.
(B) Structure of aroD in complex with a substrate-
mimicking inhibitor (PDB ID: 3N86). Substrate analog
inhibitors can bind the partially formed cavity, are capable
of inducing conformational change in the loop, and can
engage with loop residues productively.
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(interleukin-2 IL-2/IL2Ra) (Braisted et al., 2003). The authors
coupled selected fragments with a low micromolar hit to
generate the high-affinity lead compound, employing a combina-
tion of tethering, structural biology, and computational analysis.
The molecule stabilizes a conformation of IL-2 with a groove
that accommodates the small molecule and is accompanied
by repositioning the loop to embrace the furanoic acid moiety.
The protein and small molecule bind in the same region—the
adaptive hot spot—but trap very different conformations of
IL-2 (Thanos et al., 2006).
Protein surface reorganization coupled with conformational
changes was also exploited for designing novel ligands that
bind BCL-XL, a member of the BCL-2 family which inhibits
apoptosis by binding a-helical regions of the proapoptotic mole-
cules BAK and BAD (Oltersdorf et al., 2005; Petros et al., 2006;
Bruncko et al., 2007). The molecular interaction interface
between the helical peptide and the BCL-XL lacks the large
cavity characteristic of classical ligandable sites (PDB ID:
1R2D: Manion et al., 2004; Muchmore et al., 1996). An NMR
screen of around 9000 fragments in the Abbott labs gave frag-Figure 3. Conformational Flexibility of Shikimate Kinase in Response to Ligand Binding
(A) Shikimate kinase has three domains: the lid domain (LID), shikimate-binding domain (SBD), and
movements and conformational changes upon ligand binding. Depending on the sequence of ligan
mational states. Adapted from Hartmann et al. (2006).
(B) Unliganded structure of the shikimate kinase (PDB ID: 2IYT) demonstrates the absence of a liganda
conformational state.
(C) Structure of the shikimate kinase in complex with ADP and shikimate (PDB ID: 2IYQ). After the ligan
highlighted by yellow circle.
(D) Two structures representing different conformational sates (PDB ID: 2IYT and 2IYQ) are superimp
Residues from the lid domain (green) and some core residues (blue) are moved in response to ATP b
site.
46 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rights reservedment hits interacting with an initial hot spot,
and these fragments were grown toward a
second binding site. The compounds werethen systematically optimized to give ABT-737, a potent inhibitor
of BCL-XL with selectivity toward BCL-XL. A crystal structure of
ABT-737 in complex with BCL-XL (Lee et al., 2007) has subse-
quently shown that ABT-737 did not interact with the BCL-XL
in the same way as the proteins ligands, with few of the binding
interactions characteristic of the protein domain and conforma-
tional changes affecting the protein interface pockets (Figure 4;
Lee et al., 2007).
Another case where protein conformational flexibility was ex-
ploited for drug discovery was that of Imatinib inhibiting Bcr-Abl,
kinase. Imatinib was discovered using enzyme assays as the
primary screen (Capdeville et al., 2002). Early characterization
of Imatinib indicated a very high degree of selectivity toward
Bcr-Abl compared to homologs, such as Src (Zimmermann
et al., 1997; Schindler et al., 2000), an intriguing observation as
these proteins had similar structures. Structural characterization
of Imatinib-Bcr-Abl complex (Schindler et al., 2000; Nagar et al.,
2002) revealed that Imatinib targeted a unique conformation of
Bcr-ABl kinase. Compounds that were less sensitive to the
conformation of the Bcr-Abl showed were less selective (Nagar
et al., 2002; Figure 5).ATP-binding domain (ABD), all of which undergo relative
d binding, shikimate kinase can adopt one of four confor-
ble cavity, making it difficult to design ligands that bind this
d binds a new cavity is formed to accommodate the ligand,
osed. Upon shikimate binding, residues in magenta move.
inding. These conformational changes create a ligandable
Figure 4. Surface Reorganization at
a Protein-Protein Interface Mediated by
Conformational Changes
(A) Unliganded structure of the oncogenic protein
BCL-XL (PDB ID: 1R2D).
(B) Structure of BCL-XL in complex with ABT-737
(PDB ID: 2YXJ) shows that the protein surface has
undergone a significant reorganization in order to
accommodate the inhibitor.
(C) Overview of conformational changes of BCL-XL
leading to the binding of ABT-737. The core resi-
dues that remain relatively unchanged are shown
in red, whereas residues undergoing movements
in response to ligand binding are yellow. Cyan
residues are from the unliganded structure.
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Over the past decade, researchers in the pharmaceutical and
biotechnology industries and academia have made retrospec-
tive analyses of successful drug campaigns in order to establish
‘‘rules’’ to guide the selection of new target proteins. In this
review, we have focused on difficult targets, many of which
have been defined as ‘‘unligandable,’’ but which are not without
hope of providing useful drugs. One group of difficult targets,Chemistry & Biolthose that involve protein-protein interactions, has become of
increasing interest in the search for selective intervention in regu-
latory pathways that involve multiple members of superfamilies
such as protein kinases, phosphatases, and proteases. In fact,
the characteristics of binding sites at protein-protein interfaces,
particularly if they involve concerted binding and folding in the
assembly of the targeted complexes, offer new opportunities.
We have shown that, where small pockets occur at interfaces,
small fragments may be helpful in exploring the limited chemical
space.
Indeed, fragment-based approaches free the chemist from the
restraints of the large chemical screening libraries that often
reflect those compounds that have proved successful in
campaigns against classical targets such as G protein-coupled
receptors and protein kinases. They open up the possibility of
finding new chemistries that will offer efficient lead optimization.
Furthermore, fragment-based approaches make maximum use
of new sensitive biophysical techniques such as surface
plasmon resonance, isothermal calorimetry, nuclear magnetic
resonance and X-ray crystallography that can provide high-
throughput assessments of structures, kinetics, and thermody-
namics of small-molecule binding to protein targets.
The discovery of Imatinib highlighted the importance of under-
standing the population of conformers available in order to
achieve selectivity (Liu and Gray, 2006). The lesson is certainly
to define 3D structures, kinetics, and thermodynamics at every
stage of hit identification and lead optimization. However, the
challenges and rewards of targets where conformational
changes are required to configure an appropriate binding site
seem evenly balanced.
Although conformations can be stabilized that are quite
different from those that have been selected in evolution, they
nevertheless provide excellent binding sites with high ligand
efficiency. However, the desired conformations are sometimes
difficult to induce experimentally by binding fragments. The chal-
lenge here is to stabilize the unusually conformers, perhaps byFigure 5. The Selectivity of Imatinib Depends on Targeting a Unique
Conformation of Bcr-Abl
Two different activation loop conformations are shown in magenta and in
yellow. The yellow loop represents the active conformation, which is targeted
by the nonselective inhibitor (yellow spheres, PDB ID: 1M52), whereas the
magenta loop is the inactive conformation targeted by Imatinib (magenta
spheres, PDB ID: 1IEP) of the Bcr-abl kinase. The protein part that remains
relatively unchanged after ligand binding is shown in cyan color and surface is
shown.
ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 47
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Reviewprotein engineering, by crosslinking or by incorporation in a
crystal lattice.
The conformations frequently reflect relatively underpopu-
lated members of ensembles that are difficult to predict, even
with the full force of high-performance computing and efficient
molecular dynamics. This is an area where more effort is
required—and probably not just running molecular dynamics
calculations for longer. However, once conformations are
observed and rationalized, they can be exploited further and
have much to offer in drug discovery.
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